Allogene Therapeutics
ALLO
ALLO
160 hedge funds and large institutions have $1.15B invested in Allogene Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 63 increasing their positions, 51 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
5.93% more ownership
Funds ownership: 64.27% → 70.19% (+5.9%)
11% less funds holding
Funds holding: 179 → 160 (-19)
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
Holders
160
Holding in Top 10
3
Calls
$1.27M
Puts
$278K
Top Buyers
| 1 | +$61.9M | |
| 2 | +$51.2M | |
| 3 | +$42.6M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.7M |
Top Sellers
| 1 | -$28.9M | |
| 2 | -$25.3M | |
| 3 | -$13.1M | |
| 4 |
Goldman Sachs
New York
|
-$11.3M |
| 5 |
Two Sigma Investments
New York
|
-$9.06M |